Loading
Today's PV drugs control blood counts but leave the mutant cells in place. Interferon is the one treatment that shrinks the clone, and the first JAK2 V617F-selective inhibitors have entered trials; combining the two could aim at molecular remission, the way imatinib did for CML.
Polycythaemia vera is driven by a single recurrent mutation in almost every patient, yet no treatment is given with the aim of eliminating it. Ropeginterferon alfa-2b lowers the JAK2 V617F allele burden year on year in PROUD-PV and CONTINUATION-PV, and a fraction of patients reach very low burdens. Ruxolitinib blocks wild-type and mutant JAK2 alike, which limits its dose and spares the clone. Mutant-selective JAK2 V617F inhibitors are now in first-in-human trials. The idea is to test interferon plus a mutant-selective inhibitor against interferon alone with molecular response and progression, not haematocrit, as the endpoints.
One of the most cited reviews Europe PMC returns for JAK2 in Myeloproliferative neoplasms, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
One of the most cited reviews Europe PMC returns for JAK2 in Polycythaemia vera, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
One of the most cited trial reports Europe PMC returns for JAK2 in Polycythaemia vera, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
Shares Ropeginterferon alfa-2b, Polycythaemia vera (PV), JAK2, Ruxolitinib and the tags polycythaemia-vera, mpn.
Shares Ropeginterferon alfa-2b, Polycythaemia vera (PV), Ruxolitinib, Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tags polycythaemia-vera, mpn.
Shares Polycythaemia vera (PV), Ruxolitinib, Myeloproliferative neoplasms (PV, ET, myelofibrosis), Small-molecule kinase inhibitors and the tags polycythaemia-vera, mpn.
Shares Polycythaemia vera (PV), Ruxolitinib, Small-molecule kinase inhibitors and the tags polycythaemia-vera, mpn.
Shares Polycythaemia vera (PV), Ruxolitinib, Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tags polycythaemia-vera, mpn.
Shares Polycythaemia vera (PV), JAK2 and the tags polycythaemia-vera, mpn.
Shares Ropeginterferon alfa-2b, Polycythaemia vera (PV) and the tags polycythaemia-vera, mpn.
Shares Polycythaemia vera (PV), Myeloproliferative neoplasms (PV, ET, myelofibrosis) and the tags polycythaemia-vera, mpn.